Prostate Cancer News Today

July 9, 2020July 9, 2020

Vaccine Shows Promise in Advanced Prostate Cancer, Proof-of-Concept Study Shows

YourVaccx, a new type of cancer vaccine developed by ImmunSYS, is safe and shows promising effectiveness in patients with metastatic prostate cancer and other difficult-to-treat advanced solid tumors, a proof-of-concept ... Read more

June 30, 2020June 30, 2020

Ipatasertib Combo Fares Well in Early Results of IPATential150 Phase 3 Study

Prostate Cancer News Today

Adding ipatasertib to standard treatment for metastatic castration-resistant prostate cancer (mCRPC) significantly extended survival without disease worsening in a group of men whose tumors lack the PTEN protein, a Phase 3 ... Read more

June 25, 2020June 25, 2020

Relugolix Granted FDA Priority Review as New Treatment Type

Prostate Cancer News Today

The U.S. Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) Myovant Sciences submitted earlier this year requesting the approval of relugolix for the ... Read more

June 23, 2020June 23, 2020

Recommendation Against PSA Routine Screening May Have Contributed to Higher Rates of Advanced PC

Prostate Cancer News Today

The U.S. rates of advanced prostate cancer continued to rise in men 50 and older after the U.S. Preventive Services Task Force (USPSTF) recommended in 2012 against prostate-specific antigen (PSA)-based ... Read more

June 19, 2020June 19, 2020

Veyonda Aids Radiation Therapy in Reaching Distant Lesions in Late-stage Cancer Trial

Prostate Cancer News Today

Veyonda (idronoxil) given in combination with low-dose radiation therapy was able to shrink metastatic lesions well outside the radiation field in about 27% of men with late-stage metastatic castration-resistant prostate cancer (mCRPC) in the DARRT-1 Phase ... Read more

June 16, 2020June 16, 2020

Cancer DNA Levels in Blood Can Predict Treatment Responses

Prostate Cancer News Today

Analyses of circulating tumor DNA (ctDNA) — DNA from cancer cells circulating in the bloodstream — in blood samples can be used to predict which men with advanced prostate cancer ... Read more

June 11, 2020June 11, 2020

Xtandi Plus ADT Bolsters Survival in High-risk Patients, Phase 3 Trial Finds

COVID-19 News, Prostate Cancer News Today

Adding Xtandi (enzalutamide) to standard androgen deprivation therapy (ADT) significantly prolonged life by nearly a year for men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), final data from a Phase ... Read more

June 9, 2020June 9, 2020

U.K. Study to Examine Genetic Screening for Large Prostate Cancer Population

Prostate Cancer News Today

Genetic screenings of the general population for prostate cancer are feasible, safe, and may be effective at identifying the disease in apparently healthy men who might otherwise remain undiagnosed, according ... Read more

June 4, 2020June 4, 2020

NHS England Offers Xtandi, Zytiga to New PC Patients During COVID-19 Pandemic

COVID-19 News, Prostate Cancer News Today

Urged by Prostate Cancer UK, NHS England is making Xtandi (enzalutamide) and Zytiga (abiraterone acetate) available during the COVID-19 pandemic for men with newly diagnosed advanced prostate cancer. Access to ... Read more

June 2, 2020June 2, 2020

ADT May Protect Prostate Cancer Patients from COVID-19, Study Suggests

COVID-19 News, Prostate Cancer News Today

Androgen deprivation therapy (ADT), a form of hormone therapy commonly used to treat prostate cancer, appears to confer protection against the virus that causes COVID-19, lowering the rate of infections ... Read more

May 22, 2020May 22, 2020

Rubraca Receives Conditional FDA Approval for metastatic CRPC Patients with BRCA Mutations

Prostate Cancer News Today

The U.S. Food and Drug Administration (FDA) has granted conditional approval to Rubraca (rucaparib) for treating patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations who have previously received ... Read more

May 21, 2020May 21, 2020

FDA Approves Lynparza for mCRPC Patients with Mutations in DNA Repair Genes

Prostate Cancer News Today

The U.S. Food and Drug Administration has approved the oral therapy Lynparza (olaparib) for treating men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in homologous recombination repair (HRR) genes, including ... Read more

May 15, 2020May 15, 2020

Erleada Add-on Significantly Extends Survival in Non-metastatic CRPC, SPARTAN Analysis Shows

Prostate Cancer News Today

Adding Erleada (apalutamide) to androgen deprivation therapy (ADT) significantly extends the lives of men with non-metastatic castration-resistant prostate cancer (CRPC) by more than one year, a final analysis of the SPARTAN ... Read more

May 8, 2020May 8, 2020

Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds

Prostate Cancer News Today

Men with metastatic castration-resistant prostate cancer (mCRPC) showing evidence of active immune responses in their tumors live longer without disease progression after being treated with Yervoy (ipilimumab), a Phase 2 ... Read more

April 27, 2020June 1, 2020

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

COVID-19 News, Prostate Cancer News Today

While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their ... Read more